drugset / Trial / NCT02583477
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Timeline
- Start
- 2016-03-25
- Primary completion
- 2018-07-09
- Completion
- 2018-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD5069 | Small molecule | — | Oral |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |